Items where authors include "Ghia, P"

Article

Tam, CS, Robak, T, Ghia, P et al. (23 more authors) (2021) Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica, 106 (9). pp. 2354-2363. ISSN 0390-6078

Eichhorst, B, Robak, T, Montserrat, E et al. (9 more authors) (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32 (1). pp. 23-33. ISSN 0923-7534

Barrientos, JC, Hillmen, P orcid.org/0000-0001-5617-4403, Salles, G et al. (8 more authors) (2020) No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma. ISSN 1042-8194

Ghia, P, Coutre, SE, Cheson, BD et al. (7 more authors) (2020) Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. Haematologica. ISSN 0390-6078

Davids, MS, Kuss, BJ, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (13 more authors) (2020) Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. ISSN 1078-0432

O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609

Flinn, IW, Hillmen, P orcid.org/0000-0001-5617-4403, Montillo, M et al. (22 more authors) (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132 (23). pp. 2446-2455. ISSN 0006-4971

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Rawstron, AC orcid.org/0000-0003-0798-9790, Kreuzer, K-A, Soosapilla, A et al. (30 more authors) (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B: Clinical Cytometry, 94 (1). pp. 121-128. ISSN 1552-4949

Brown, JR, Moslehi, J, O' Brien, S et al. (24 more authors) (2017) Characterization Of Atrial Fibrillation Adverse Events Reported In Ibrutinib Randomized Controlled Registration Trials. Haematologica, 102 (10). pp. 1796-1805. ISSN 0390-6078

Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793

Proceedings Paper

Burger, J, Tedeschi, A, Barr, PM et al. (32 more authors) (2016) International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: Oncology Research and Treatment. Annual conference of the German, Austrian and Swiss Societies for Haematology and Medical Oncology, 14-18 Oct 2016, Leipzig, Germany. Karger Publishers , p. 6.